Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.89 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.89 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.89 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.89 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.89 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581394 | 1.00 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3581391 | 1.00 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8227560 | 0.97 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3587018 | 0.97 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2886698 | 0.95 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13503486 | 0.94 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8230471 | 0.94 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3584832 | 0.94 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3587830 | 0.94 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8231274 | 0.94 | PSEN1 (0.79) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013171-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE | MERCK SHARP & DOHME (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | disclosed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | disclosed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | disclosed |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| WO-2007125364-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | PSEN1 2/4885PSEN2 4/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.